Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection S

LAS VEGAS, March 11 /PRNewswire/ -- Altogen Biosystems (http://www.altogen.com) announced launch of new contract research services. Located in Las Vegas, NV, Altogen Custom Services focus on providing specialized biotechnology and pharmaceutical services, including RNA Interference (RNAi) services, generation of stably-expressing cell lines, assay development, screening and transfection services. In particular, the company will draw upon their unique experience with over hundred cancer cell lines and expertise in polymer and nanoparticle-based gene delivery technologies.

Generation of stably-expressing cancer cell lines and primary cells can be very expensive and time-consuming. Utilizing this method, investigators are able to develop cells that permanently express specific genes through their incorporation in the cellular genome. Altogen Custom Services offers generation of stable cell lines by transforming the cell line of choice to stably express vector or gene of interest. Optional cloning and shRNA expression services are available. The service turnaround time is typically 3-4 weeks.

Altogen laboratory research services (http://www.altogen.com/support.htm) include:

About Altogen Biosystems

Altogen Biosystems is a life sciences company dedicated to the development, marketing and manufacture of In Vivo and In Vitro transfection reagents for intracellular and tissue-targeted delivery of biomolecules. Altogen Custom Services is a laboratory contract research organization. It provides specialized contract research to pharmaceutical, biotechnology, and other life science organizations worldwide. For more information visit http://www.altogen.com

SOURCE Altogen Biosystems

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.